Henry Schein, Inc. (HSIC)
Why Henry Schein (HSIC) is Poised to Beat Earnings Estimates Again
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Williams, Henry Schein, and 3 Other Bargain Stocks From a Veteran Value Fund Manager
Ari Sass of the M.D. Sass Concentrated Value ETF is hunting for reasonably priced growth stocks like Henry Schein.
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein (HSIC) Down 9.4% Since Last Earnings Report: Can It Rebound?
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
Should You Retain Henry Schein Stock in Your Portfolio for Now?
HSIC's growth from its Henry Schein One venture and partnerships is promising, but macro pressures and stiff competition raise concerns for investors.
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Analyzing Cooper Companies (NASDAQ:COO) and Henry Schein (NASDAQ:HSIC)
Cooper Companies (NASDAQ: COO - Get Free Report) and Henry Schein (NASDAQ: HSIC - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Earnings and Valuation This table compares Cooper Companies
Henry Schein: Still A Buy - But Caution Is Warranted
Henry Schein, Inc. is rated a 'Buy' as signs of improving growth and undervaluation emerge despite recent stagnation. HSIC's recent results show solid revenue and EPS growth, but operating margins and ROIC remain pressured, challenging its economic moat. Management guides for 3–5% sales growth and 5–8% non-GAAP EPS growth in 2026, supported by strategic focus on high-margin businesses and digital transformation.
Henry Schein, Inc. (HSIC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Henry Schein, Inc. (HSIC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Henry Schein, Inc. (HSIC) Presents at Leerink Global Healthcare Conference 2026 Transcript
Henry Schein, Inc. (HSIC) Presents at Leerink Global Healthcare Conference 2026 Transcript
